When your patient presents with AKs, refer them to a Metvix Specialist for patient and physician preferred AK treatment.1-4


Indications and Clinical Use:

METVIX cream in combination with 630 nm wavelength red light illumination using the Aktilite CL 128 lamp (conventional photodynamic therapy [c-PDT]) is indicated for the:

  • treatment of thin or non-hyperkeratotic and non-pigmented actinic keratosis on the face and scalp when other therapies are considered less appropriate.
  • treatment of primary superficial basal cell carcinoma outside the H-zone of the face (e.g. ears, nose) when other therapies are considered less appropriate. The lesions should have been confirmed previously by biopsy.
Contraindications:
  • Patients who are hypersensitive to aminolevulinic acid or peanut and almond oil, or any of the ingredients in Metvix or porphyrins.
  • Patients with cutaneous photosensitivity/porphyria, or known allergies to porphyrins
  • Patients with morpheaform basal cell carcinoma.
Most Serious Warnings and Precautions:
  • METVIX cream is intended for topical use. Do not apply to the eyes or to mucous membranes.
  • METVIX should be administered by trained healthcare professionals only.
  • Care should be taken when applying METVIX cream to avoid inadvertent skin contact.
  • Patients with sBCC treated with METVIX c-PDT must have regular follow- up of the treatment site since the efficacy is generally less than with surgery.
  • The long-term efficacy of METVIX c-PDT for the treatment of sBCC has not been established. Data from studies performed with a different lamp showed that the sBCC lesion complete response (CR) at 12 months was similar to that observed with the Aktilite CL128 lamp, but decreased to 29- 60% at 60 months post-treatment.

References: 1. See JA, et al. Dermatol Ther 2017;7(4):525–33. 2. Fargnoli MC, et al. J Eur Acad Dermatol Venereol 2018;32(5):757–62. 3. Morton C, et al. Br J Dermatol 2006;155(5):1029–36. 4. Szeimies RM, et al. J Am Acad Dermatol 2002;47(2):258–62.

© 2022 Galderma Canada Inc.

All trademarks are the property of their respective owners.
Galderma Canada Inc. 55 Commerce Valley Drive W., Suite 400 Thornhill, Ontario L3T 7V9

GALDERMA est.1981